PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsRifapentine
Rifapentine
Priftin (rifapentine) is a small molecule pharmaceutical. Rifapentine was first approved as Priftin on 1998-06-22. It is used to treat latent tuberculosis, mycobacterium infections, and pulmonary tuberculosis in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
respiratory tract diseasesD012140
Trade Name
FDA
EMA
Priftin
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Rifapentine
Tradename
Company
Number
Date
Products
PRIFTINSanofiN-021024 RX1998-06-22
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
priftinNew Drug Application2025-05-21
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
J: Antiinfectives for systemic use
— J04: Antimycobacterials
— J04A: Drugs for treatment of tuberculosis
— J04AB: Antibiotics, antitubercular
— J04AB05: Rifapentine
HCPCS
No data
Clinical
Clinical Trials
73 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
TuberculosisD014376EFO_0000774A15-A1914182681066
Latent tuberculosisD055985—Z22.764124426
InfectionsD007239EFO_0000544—2261111
HivD006678—O98.7221116
Chronic kidney failureD007676EFO_0003884N18.6———2—2
Kidney diseasesD007674EFO_0003086N08———2—2
Hiv seropositivityD006679——11—1—2
Patient complianceD010349—————1—1
Renal insufficiencyD051437—N19———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Pulmonary tuberculosisD014397EFO_1000049A15166——11
Hiv infectionsD015658EFO_0000764B20233—310
Communicable diseasesD003141——123—16
Mycobacterium infectionsD009164—A31.9111——3
Acquired immunodeficiency syndromeD000163EFO_0000765B201—1—13
Mycobacterium tuberculosisD009169NCBITaxon_1773—1—1——2
SilicosisD012829EFO_0007485J62——1—12
Latent infectionD000085343———11—12
Diabetes mellitusD003920EFO_0000400E08-E13——1——1
InfertilityD007246EFO_0000545———1——1
Show 4 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Mycobacterium avium-intracellulare infectionD015270EFO_0007386——1———1
BacteremiaD016470EFO_0003033R78.81—1———1
Respiratory tract infectionsD012141—J06.911———1
PregnancyD011247EFO_0002950Z33.111———1
Spinal tuberculosisD014399—A18.01—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———3————3
OsteomyelitisD010019EFO_0003102M861————1
Drug interactionsD004347——1————1
Breast feedingD001942——1————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Opioid-related disordersD009293EFO_0005611F11————11
HepatitisD006505—K75.9————11
Addictive behaviorD016739EFO_0004347—————11
SilicotuberculosisD012830—J65————11
Only childD009863——————11
Adolescent developmentD041923——————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameRifapentine
INNrifapentine
Description
Rifapentine, sold under the brand name Priftin, is an antibiotic used in the treatment of tuberculosis. In active tuberculosis it is used together with other antituberculosis medications. In latent tuberculosis it is typically used with isoniazid. It is taken by mouth.
Classification
Small molecule
Drug classantibiotics (rifamycin derivatives)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C6CCCC6)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C
Identifiers
PDB—
CAS-ID61379-65-5
RxCUI—
ChEMBL IDCHEMBL1660
ChEBI ID45304
PubChem CID6323497
DrugBankDB01201
UNII IDXJM390A33U (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 4,190 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
339 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use